Hepatitis A

1. Clinical Overview

Summary

Hepatitis A is an acute, self-limiting viral liver infection caused by the Hepatitis A Virus (HAV), a single-stranded RNA virus belonging to the Picornaviridae family. It is transmitted predominantly via the faecal-oral route, typically through contaminated water, food (particularly shellfish and raw produce), or direct person-to-person contact. Unlike Hepatitis B and C, HAV infection never causes chronic liver disease or a chronic carrier state, and it confers lifelong immunity following recovery. [1,2]

The disease demonstrates significant geographic variation in endemicity, with high prevalence in regions with poor sanitation and hygiene infrastructure. In developed countries, most cases are imported through international travel or occur in specific at-risk populations including men who have sex with men (MSM), people who inject drugs (PWID), and individuals with chronic liver disease. [3]

Clinical Pearls

Cigarette Aversion: A surprisingly specific prodromal symptom. Smokers will suddenly lose their taste for tobacco days before the jaundice appears. This phenomenon is thought to reflect altered hepatic metabolism and changes in taste perception associated with acute hepatocellular injury.

The "Filter Feeder" Risk: Bivalve molluscs (oysters, mussels, clams) filter enormous volumes of water—up to 15 liters per hour. If the water is contaminated with sewage containing HAV, the virus concentrates in their digestive tissues. Consumption of raw or undercooked shellfish, particularly from warm coastal waters, represents a classic high-risk exposure. [4]

Post-Exposure Prophylaxis Window: Unlike many viruses, the Hepatitis A vaccine demonstrates efficacy when administered after exposure. If given within 14 days to contacts, it can prevent or significantly attenuate the disease through rapid induction of active immunity. This reflects the relatively long incubation period of HAV. [5]

Age-Paradox of Severity: Children typically experience mild or asymptomatic infection, while adults develop more severe disease with higher rates of jaundice and complications. This inverse relationship between age and symptom severity is unusual among viral infections and reflects immunological factors rather than viral virulence. [6]

---

2. Epidemiology

Global Distribution

Hepatitis A demonstrates marked geographic variation based on sanitation infrastructure and socioeconomic development. The World Health Organization classifies regions by endemicity:

High Endemicity (Africa, South Asia, Central America):

• Most children infected by age 10
• Paradoxically low disease burden due to asymptomatic childhood infection
• Adults often immune, minimal symptomatic disease
• Poor water treatment and sanitation infrastructure

Intermediate Endemicity (Eastern Europe, Middle East, parts of Asia):

• Mixed exposure patterns
• Shifting epidemiology with improving sanitation
• Outbreaks in adolescents and young adults
• Increasing susceptibility in older populations

Low Endemicity (Western Europe, North America, Australia, Japan):

• Minimal childhood exposure
• Most adults susceptible
• Cases primarily travel-associated
• Outbreaks in specific risk groups
• Higher proportion of symptomatic disease [3,7]

United Kingdom Epidemiology

In the UK, Hepatitis A incidence has declined significantly over the past three decades, from approximately 5,000 cases annually in the 1990s to fewer than 1,000 cases in recent years. Key epidemiological features include:

• Travel-associated cases: 70-80% of reported cases have recent travel to endemic areas, particularly South Asia, North Africa, and Central/South America
• Foodborne outbreaks: Periodic outbreaks associated with imported produce (berries, salads) or shellfish
• MSM outbreaks: Cyclical outbreaks in men who have sex with men, linked to oral-anal sexual practices
• PWID outbreaks: Hepatitis A transmission among people who inject drugs, often concurrent with Hepatitis B and C
• Household secondary cases: Attack rate of 15-30% among household contacts of index cases [8]

Transmission Dynamics

Primary Routes:

1. Faecal-Oral (Predominant):

   • Contaminated water sources (wells, recreational water)
   • Food contaminated by infected food handlers
   • Direct person-to-person spread (poor hand hygiene)
   • Highest viral shedding: 2 weeks before to 1 week after jaundice onset

2. Sexual Transmission:

   • Oro-anal contact (rimming) in MSM populations
   • Recognized as significant route in outbreak settings
   • May account for 10-15% of cases in some urban settings

3. Blood-Borne Transmission (Rare):

   • Transfusion-related transmission is extremely rare
   • Viraemia is brief (1-2 weeks) and low titre
   • Transmission among PWID through needle-sharing
   • Blood donor screening not routinely performed in most countries [9]

Demographics and Risk Factors

High-Risk Populations:

Age-Related Attack Rates:

• Children less than 6 years: 70% asymptomatic (anicteric)
• Children 6-14 years: 40-50% asymptomatic
• Adults > 14 years: 70-80% symptomatic with jaundice
• Adults > 50 years: 85-90% symptomatic, increased severity [6,10]

Seasonal Variation

Unlike many viral infections, Hepatitis A does not demonstrate strong seasonal variation in endemic regions due to continuous faecal-oral transmission. In low-endemicity countries, slight peaks may occur in late summer/autumn corresponding to the return of travellers following summer holidays and the school year re-commencement facilitating institutional transmission.

---

3. Virology and Molecular Biology

Viral Structure

Hepatitis A Virus (HAV) is a non-enveloped, single-stranded, positive-sense RNA virus classified within the genus Hepatovirus of the family Picornaviridae. Key structural features include:

• Genome: 7.5 kb linear RNA encoding a single polyprotein
• Capsid: Icosahedral symmetry, 27-32 nm diameter
• Stability: Remarkably stable in the environment
  • Survives at room temperature for weeks to months
  • Resistant to pH 3-10 (acid and alkaline stable)
  • "Heat-resistant: Requires > 85°C for 1 minute for inactivation"
  • "Chlorine-resistant: Requires higher concentrations than standard water treatment"
  • Freezing does not inactivate the virus [1,11]

Inactivation Methods:

• Heat: > 85°C × 1 minute
• Chlorine: 1-2 mg/L free chlorine × 30 minutes
• Formalin: Used in vaccine production
• UV radiation: Effective in water treatment
• Sodium hypochlorite (bleach): 1:100 dilution for surface disinfection

Viral Replication Cycle

1. Entry: Virus binds to cellular receptor (TIM-1, HAVcr-1) on hepatocyte surface
2. Uncoating: Receptor-mediated endocytosis, release of RNA into cytoplasm
3. Translation: Viral RNA functions as mRNA, translated as single polyprotein
4. Polyprotein Processing: Viral proteases cleave polyprotein into structural and non-structural proteins
5. RNA Replication: RNA-dependent RNA polymerase synthesizes negative-strand intermediate, then positive-strand progeny genomes
6. Assembly: Capsid proteins assemble around genomic RNA
7. Release: Virus exits cell through:
   • Direct cytolysis (traditional view)
   • Exosome-like vesicles (quasi-enveloped particles) - recently described mechanism allowing cell-to-cell spread without immune detection [12]

Genotypes

HAV demonstrates limited genetic diversity with six genotypes (I-VI) and multiple sub-genotypes. Genotypes I-III infect humans, with genotypes IV-VI restricted to simians:

• Genotype I: Most common worldwide (subtypes IA and IB)
• Genotype II: Less common, sporadic cases
• Genotype III: Rare, sporadic cases
• All genotypes belong to a single serotype (monotypic)
• Genotype does not correlate with disease severity
• Genotype analysis useful for outbreak investigation and molecular epidemiology [13]

Viral Persistence in Environment

HAV's environmental stability is exceptional among hepatitis viruses, contributing to its efficient faecal-oral transmission:

---

4. Pathophysiology

Mechanism of Hepatocellular Injury

The pathogenesis of Hepatitis A is immunologically mediated rather than due to direct viral cytopathic effects. This fundamental principle explains key clinical features:

Immunopathogenesis Cascade:

1. Viral Entry and Replication (Weeks 1-2 post-infection):

   • Virus ingested, survives gastric acid
   • Absorbed across intestinal epithelium
   • Portal venous transport to liver
   • Binds to hepatocyte receptors (TIM-1/HAVcr-1)
   • Replicates within hepatocyte cytoplasm
   • Minimal hepatocellular damage during early replication phase

2. Biliary Excretion and Faecal Shedding (Weeks 2-4):

   • Newly formed virions transported to bile canaliculi
   • Excreted in bile into intestinal tract
   • Peak faecal viral shedding occurs before symptom onset
   • Explains high transmission during incubation period

3. Immune Recognition and Activation (Weeks 3-5):

   • Viral antigens presented on MHC Class I (all infected hepatocytes)
   • CD8+ cytotoxic T lymphocytes recognize viral peptides
   • CTL activation and expansion
   • NK cell activation and IFN-γ production

4. Hepatocellular Injury Phase (Weeks 4-8):

   • Primary mechanism: CTL-mediated apoptosis of infected hepatocytes
   • Perforin/granzyme pathway induces apoptosis
   • Fas-FasL interaction augments cell death
   • Release of intracellular enzymes (ALT/AST) into serum
   • Inflammatory infiltrate in portal tracts and lobules
   • Cholestasis from bile duct inflammation and hepatocyte dysfunction

5. Viral Clearance and Recovery (Weeks 6-12):

   • Neutralizing antibodies (IgG anti-HAV) appear
   • Viral replication ceases
   • Clearance of infected hepatocytes
   • Hepatocyte regeneration begins
   • Resolution of inflammation
   • No chronic infection: RNA virus with effective immune clearance [2,14]

Histopathological Features

Liver biopsy (rarely performed clinically) demonstrates characteristic patterns:

Acute Phase:

• Portal and periportal inflammation (lymphocytes, plasma cells)
• Hepatocellular necrosis (spotty and confluent)
• Ballooning degeneration of hepatocytes
• Cholestasis (bile plugs in canaliculi)
• Kupffer cell hypertrophy
• Preservation of reticulin framework (no fibrosis)
• Rosette formation (regenerating hepatocytes)

Severe Cases:

• Bridging necrosis (portal-portal or portal-central)
• Submassive necrosis (> 50% of hepatocytes)
• Massive necrosis (acute liver failure pattern)

Cholestatic Variant:

• Marked canalicular and ductular cholestasis
• Minimal hepatocellular necrosis
• Prominent inflammatory infiltrate
• Ductular reaction

Recovery Phase:

• Resolution of inflammation
• Complete hepatocyte regeneration
• No fibrosis or architectural distortion
• Normal liver histology within 6 months [15]

Immunological Response

Innate Immunity:

• Type I interferons (IFN-α/β) induced within hours
• NK cells activated, produce IFN-γ
• Complement activation (minimal role)
• Inflammatory cytokines (TNF-α, IL-6)

Adaptive Immunity:

Lifelong Immunity:

• Single serotype ensures immunity to all strains
• IgG anti-HAV persists for decades (possibly lifelong)
• Memory B cells provide anamnestic response
• Reinfection extremely rare (case reports disputed)
• Vaccine-induced immunity lasts > 25 years, possibly lifelong [16]

Factors Influencing Disease Severity

Age: Most significant predictor

• Children less than 6 years: 70% asymptomatic, case fatality less than 0.1%
• Adults 15-39 years: Symptomatic, case fatality 0.1-0.3%
• Adults > 40 years: Severe disease, case fatality 0.3-1%
• Adults > 50 years: Highest severity, case fatality 1.5-2.7%

Underlying Liver Disease:

• Chronic Hepatitis B/C: 10-fold increased mortality
• Alcoholic liver disease: Higher risk of fulminant failure
• NAFLD/NASH: Increased risk of complications
• Autoimmune hepatitis: Risk of severe flare
• Wilson's disease, hemochromatosis: Accelerated decompensation

Comorbidities:

• HIV infection: May have prolonged viraemia
• Immunosuppression: Potential for prolonged shedding
• Pregnancy: Higher risk of complications in third trimester
• Malnutrition: May influence severity

Genetic Factors:

• HLA alleles may influence disease susceptibility and severity
• Polymorphisms in immune response genes under investigation [17]

---

5. Clinical Presentation

Incubation Period

• Average: 28 days (range 15-50 days)
• Infectious period: Begins 2 weeks before jaundice, peaks just before symptom onset
• Duration of shedding: Typically 1-2 weeks after jaundice onset in immunocompetent adults
• Prolonged shedding: Up to 6 months in neonates and immunocompromised patients

Clinical Implication: The infectious period precedes symptoms, making isolation ineffective for outbreak prevention. The emphasis must be on vaccination of contacts and public health measures.

Clinical Phases

Phase 1: Prodromal (Pre-icteric) Phase (3-10 days):

Onset is typically abrupt with non-specific constitutional symptoms:

• Systemic symptoms:

  • Fever (38-39°C) in 70% - usually low-grade
  • Profound fatigue and malaise (nearly universal)
  • Myalgia and arthralgia
  • Headache
  • Rigors (less common)

• Gastrointestinal symptoms:

  • Anorexia (near universal) - often profound
  • Nausea and vomiting (70-80%)
  • Right upper quadrant pain (60%) - from hepatic capsule distension
  • Diarrhoea (20-40%)
  • Altered taste perception
  • Cigarette aversion in smokers (highly specific)

• Laboratory:

  • ALT/AST begin to rise (detectable at end of prodrome)
  • Viral shedding in stool reaches peak levels
  • IgM anti-HAV becomes positive just before or at symptom onset

Phase 2: Icteric Phase (1-3 weeks):

Constitutional symptoms often improve as jaundice develops (paradoxical improvement):

• Jaundice (70-80% of adults):

  • Scleral icterus appears first
  • Progressive yellowing of skin
  • Dark urine (bilirubinuria) - often precedes visible jaundice
  • Pale stools (cholestasis) - described as "clay-colored"
  • Urine may appear tea-colored or cola-colored

• Pruritus (20-40%):

  • Varies from mild to severe
  • Due to bile salt deposition in skin
  • May persist for weeks
  • Worse in cholestatic variant

• Hepatomegaly (85%):

  • Liver edge tender, smooth, palpable 2-4 cm below costal margin
  • Hepatic tenderness on percussion (common)

• Splenomegaly (15-20%):

  • Usually mild if present

• Laboratory:

  • Peak ALT/AST (typically > 1000 IU/L, often > 2000 IU/L)
  • Total bilirubin elevated (usually 5-15 mg/dL, may exceed 20 mg/dL)
  • Alkaline phosphatase mildly elevated (1.5-3× ULN)
  • IgM anti-HAV strongly positive
  • Faecal viral shedding declining

Phase 3: Convalescent Phase (Weeks to months):

• Gradual resolution of jaundice (2-4 weeks typically)
• Normalization of bilirubin
• Slow decline of transaminases (may take 3-6 months)
• Persistent fatigue common (may last months)
• Complete recovery expected by 6 months in > 95% [6,18]

Age-Related Clinical Spectrum

Neonates and Infants (less than 1 year):

• Usually asymptomatic
• May present with non-specific symptoms (irritability, poor feeding)
• Prolonged viral shedding (up to 6 months)
• Source of household transmission

Children (1-5 years):

• 70-90% asymptomatic or anicteric
• Mild non-specific illness if symptomatic
• Diagnosis often missed
• Important reservoir in outbreaks

Children (6-14 years):

• 40-60% symptomatic
• Milder course than adults
• Complications rare

Adults (15-39 years):

• 70-80% symptomatic with jaundice
• Moderate to severe symptoms
• Prolonged fatigue common
• Complications uncommon

Older Adults (≥40 years):

• 80% symptomatic

• More severe illness
• Higher rates of complications
• Longer convalescence
• Increased risk of fulminant hepatic failure [10]

Atypical Presentations

Cholestatic Hepatitis A (5-10% of cases):

• Prolonged jaundice (> 3 months, may persist 6-12 months)
• Severe pruritus (dominant symptom)
• High bilirubin (often > 15 mg/dL)
• Moderately elevated ALP
• Minimal transaminase elevation (typically less than 500 IU/L)
• Benign course - always resolves
• May require corticosteroid therapy for severe pruritus
• Bile duct imaging normal (distinguishes from biliary obstruction)

Relapsing Hepatitis A (10-15% of cases):

• Initial recovery followed by recurrence of symptoms
• Typically 30-90 days after initial episode
• Second wave may be as severe as first
• Characterized by:
  • Recurrent jaundice
  • Re-elevation of transaminases
  • Reappearance of IgM anti-HAV (may be persistent from initial episode)
  • Viral shedding resumes in stool
• Multiple relapses possible (up to 3-4 episodes reported)
• All relapses eventually resolve
• Total illness duration may extend to 6-9 months

Fulminant Hepatic Failure (0.1-0.4% overall):

• See Section 8 (Complications) for detailed discussion
• Defined as encephalopathy + coagulopathy within 8 weeks of symptom onset
• Higher risk in:
  • Age > 50 years (2-3%)
  • Underlying chronic liver disease (10-30%)
  • Chronic Hepatitis B or C co-infection
• Mortality 50-80% without liver transplantation

Extrahepatic Manifestations (Rare):

• Arthralgia/arthritis (5-10%)
• Cutaneous vasculitis (immune complex deposition)
• Cryoglobulinemia
• Glomerulonephritis (immune complex-mediated)
• Aplastic anaemia (extremely rare, case reports)
• Autoimmune hepatitis (HAV as trigger, controversial)
• Guillain-Barré syndrome (case reports, causal link uncertain) [19]

---

6. Clinical Examination

General Inspection

Patient Appearance:

• Visibly jaundiced in icteric phase
• Appears unwell, fatigued
• May have scratch marks from pruritus
• Dehydration possible if severe vomiting

Vital Signs:

• Temperature: May be febrile in prodrome (38-39°C), usually afebrile in icteric phase
• Pulse: Normal or mildly elevated
• Blood pressure: Usually normal
• Respiratory rate: Normal

Jaundice Assessment

Scleral Icterus:

• Examine under natural light
• Best visualized in lateral sclera
• Earliest sign of hyperbilirubinemia (detectable at bilirubin > 2.5 mg/dL)
• Compare with non-jaundiced individual if uncertain

Skin Jaundice:

• Yellow discoloration of skin
• Best appreciated in natural light
• Starts with face, progresses caudally
• Bilirubin typically > 3 mg/dL for visible skin jaundice

Differential Diagnosis of Yellow Discoloration:

• Carotenemia: Spares sclerae, palms/soles affected
• Quinacrine ingestion
• Phenol exposure

Abdominal Examination

Inspection:

• No specific findings in uncomplicated Hepatitis A
• Assess for signs of chronic liver disease (should be absent): spider naevi, palmar erythema, gynaecomastia, caput medusae

Palpation:

Percussion:

• Liver span: May be increased (normal 6-12 cm in midclavicular line)
• Percussion tenderness over liver (common)

Auscultation:

• Bowel sounds: Normal
• Hepatic bruit: Absent (if present, consider hepatocellular carcinoma)

Lymphatic Examination

• Cervical lymphadenopathy: Occasionally present (10-15%), small, non-tender nodes
• Generalized lymphadenopathy: Uncommon, if present suggests alternative diagnosis (EBV, CMV, HIV seroconversion)

Neurological Examination

Critical in Risk Assessment:

• Level of consciousness: Must be normal in uncomplicated cases
• Asterixis (Flapping Tremor): ABSENT in uncomplicated Hepatitis A
  • "If present: Indicates hepatic encephalopathy → Acute liver failure"
  • "Test: Arms outstretched, wrists dorsiflexed, observe for irregular jerking movements"
• Confusion, disorientation: RED FLAG - suggests encephalopathy
• Grade encephalopathy if present (West Haven Criteria):
  • "Grade I: Altered mood, impaired attention"
  • "Grade II: Drowsiness, confusion, inappropriate behavior"
  • "Grade III: Somnolent but rousable, marked confusion"
  • "Grade IV: Coma"

Signs of Decompensated Liver Disease

Should be ABSENT in uncomplicated Hepatitis A (if present, consider chronic liver disease):

• Spider naevi (> 5)
• Palmar erythema
• Leukonychia
• Clubbing
• Dupuytren's contracture
• Gynaecomastia
• Testicular atrophy
• Loss of axillary/pubic hair
• Caput medusae
• Peripheral edema
• Ascites

Red Flag Signs Requiring Urgent Assessment

---

7. Investigations

Diagnostic Serology (Definitive)

Serological testing is the cornerstone of Hepatitis A diagnosis:

Anti-HAV IgM:

• Interpretation: Positive = Acute HAV infection
• Timing: Detectable at symptom onset, peaks at 1-2 weeks
• Duration: Persists for 3-6 months (occasionally up to 12 months)
• Sensitivity: > 99% during acute illness
• Specificity: > 99%
• False Positives: Rare (rheumatoid factor interference, other acute infections)
• Clinical Use: GOLD STANDARD for diagnosis of acute Hepatitis A

Anti-HAV IgG:

• Interpretation: Positive = Past infection OR vaccination
• Timing: Appears 2-4 weeks after symptom onset
• Duration: Lifelong (detectable for decades)
• Clinical Use:
  • Determine immunity status pre-travel
  • Distinguish acute from past infection (IgM negative, IgG positive = past infection)
  • Post-vaccination immunity confirmation

Total Anti-HAV (IgM + IgG combined):

• Less useful for acute diagnosis
• Does not distinguish acute from past infection
• May be used for immunity screening

Serological Patterns:

Liver Function Tests

Transaminases (Hepatocellular Injury Markers):

• ALT (Alanine Aminotransferase):

  • Typically 1000-5000 IU/L (can exceed 10,000 IU/L)
  • More specific for liver injury than AST
  • Begins rising in late prodrome
  • Peaks during icteric phase
  • Returns to normal over 1-6 months

• AST (Aspartate Aminotransferase):

  • Similar pattern to ALT
  • AST/ALT ratio typically less than 1 (hepatocellular pattern)
  • AST/ALT ratio > 2 suggests alcohol or chronic liver disease

Bilirubin:

• Total Bilirubin: 5-15 mg/dL (mild to moderate cases), may exceed 20 mg/dL
• Direct (Conjugated) Bilirubin: Predominates (> 50% of total)
• Indirect (Unconjugated) Bilirubin: Elevated due to hepatocellular dysfunction
• Bilirubinuria: Direct bilirubin excreted in urine (dark urine)

Alkaline Phosphatase (ALP):

• Mildly elevated (1.5-3× upper limit of normal)
• Marked elevation (> 5× ULN) suggests cholestatic variant

Gamma-Glutamyl Transferase (GGT):

• Elevated in parallel with ALP
• Helps confirm hepatic origin of elevated ALP

Albumin:

• Usually normal (hepatic synthetic function preserved in acute uncomplicated HAV)
• Low albumin suggests chronic liver disease or severe acute injury

Coagulation Studies (Critical for Severity Assessment)

Prothrombin Time (PT) / INR:

• Normal INR (less than 1.2): Uncomplicated hepatitis, good prognosis
• INR 1.2-1.5: Moderate hepatic dysfunction, close monitoring required
• INR > 1.5: RED FLAG - Severe hepatic dysfunction, risk of acute liver failure
• INR > 2.0: High risk of bleeding, encephalopathy
• INR > 3.0: Very high risk, consider intensive care

Clinical Significance:

• PT/INR is the most important prognostic marker
• Reflects hepatic synthetic function (Factor II, VII, IX, X production)
• Rising INR despite clinical improvement = RED FLAG
• INR > 1.5 + encephalopathy = Acute Liver Failure (by definition)

aPTT:

• May be prolonged in severe cases
• Less useful than PT/INR for monitoring

Complete Blood Count

• Leukopenia: Common (lymphopenia in prodrome, may normalize later)
• Atypical lymphocytes: May be present (10-20% of cases)
• Thrombocytopenia: Mild, if present
• Hemoglobin: Normal (unless bleeding complication)

Renal Function

• Urea and Creatinine: Monitor for dehydration (from vomiting) or hepatorenal syndrome
• Electrolytes: Monitor for hyponatremia, hypokalemia (vomiting)

Additional Investigations in Selected Cases

Hepatitis B and C Serology:

• Indication: All patients with acute hepatitis
• Rationale:
  • Rule out co-infection
  • Identify underlying chronic viral hepatitis (higher risk of severe disease)
  • Influence management and prognosis

Hepatitis E Serology:

• Indication: Travel to endemic areas, pregnancy, severe disease
• Rationale: Clinical presentation identical to HAV, differentiation essential in pregnancy

HIV Testing:

• Consider in at-risk populations (MSM, PWID)
• HIV may alter HAV natural history

Autoimmune Markers (ANA, ASMA, Anti-LKM, IgG):

• Indication: Atypical features, very high transaminases, prolonged course
• Rationale: Exclude autoimmune hepatitis

Paracetamol Level:

• Indication: History of use, very high transaminases
• Rationale: Drug-induced liver injury is important differential

Ceruloplasmin and Copper Studies:

• Indication: Young patients (less than 40 years) with severe acute hepatitis
• Rationale: Wilson's disease can present as acute liver failure

Imaging Studies

Ultrasound Abdomen:

• Indication:
  • Cholestatic pattern (high ALP, high bilirubin)
  • Abdominal pain
  • Rule out biliary obstruction
• Findings in Hepatitis A:
  • Hepatomegaly (diffuse, homogeneous)
  • Normal bile ducts (distinguishes from obstruction)
  • Gallbladder wall thickening (occasional)
  • Splenomegaly (15%)
  • Increased portal lymph nodes (reactive)
  • Normal vasculature (portal vein patent)
• Alternative Diagnoses:
  • Choledocholithiasis (dilated CBD)
  • Cholecystitis (thickened GB wall, stones, Murphy's sign)
  • Hepatic abscess
  • Hepatocellular carcinoma

CT Abdomen (Rarely Required):

• Indication: Suspected mass, abscess, vascular complications
• Not routinely indicated for Hepatitis A

MRCP:

• Indication: Suspected biliary obstruction with normal ultrasound
• Not routinely indicated for Hepatitis A

Liver Biopsy

Indication: Almost never required for diagnosis

• Diagnosis is serological (IgM anti-HAV)
• Biopsy reserved for diagnostic uncertainty (e.g., possible autoimmune hepatitis, drug-induced liver injury)

Contraindications:

• Coagulopathy (INR > 1.5, Platelets less than 50,000)
• Ascites
• Uncooperative patient

Monitoring Investigations

Acute Phase (Weekly until improving):

• LFTs (ALT, Bilirubin)
• INR (critical)
• Renal function and electrolytes

Recovery Phase (Every 2-4 weeks until normal):

• LFTs
• Resolution of transaminase elevation confirms recovery

---

8. Management

Management Algorithm

        SUSPECTED ACUTE VIRAL HEPATITIS
        (Jaundice, High Transaminases)
                 ↓
        DIAGNOSTIC WORKUP
        - IgM Anti-HAV (diagnostic)
        - LFTs, INR, FBC, U&E
        - HBV, HCV, HEV serology
                 ↓
        HEPATITIS A CONFIRMED
        (IgM Anti-HAV Positive)
                 ↓
    SEVERITY ASSESSMENT
    ┌──────────────┴──────────────┐
    ↓                              ↓
UNCOMPLICATED              SEVERE DISEASE
(INR less than 1.5,                 (INR ≥1.5 OR
No encephalopathy,         Encephalopathy OR
Age less than 50,                   Age > 50 + severe symptoms OR
No CLD)                    Underlying CLD)
    ↓                              ↓
OUTPATIENT MANAGEMENT      HOSPITAL ADMISSION
- Supportive care          - Specialist hepatology unit
- Rest, hydration          - ICU if encephalopathy
- Avoid hepatotoxins       - 4-hourly observations
- Avoid alcohol            - Daily LFTs, INR
- Monitor symptoms         - Transplant evaluation if fulminant
- Safety-netting           - IV fluids if vomiting
- Follow-up LFTs           - Nutrition support
    ↓                              ↓
PUBLIC HEALTH MEASURES     SPECIFIC INTERVENTIONS
- Notify local authority   - N-acetylcysteine (if indicated)
- Identify contacts        - Lactulose if encephalopathy
- Post-exposure prophylaxis- Vitamin K (if INR elevated)
  (Vaccine within 14 days) - Transplant listing (if ALF)
- Food handler exclusion   
- School/nursery exclusion 
    ↓                              ↓
RECOVERY MONITORING        INTENSIVE MONITORING
- LFTs every 2-4 weeks     - 4-hourly neurological obs
- Return to work when      - Daily coagulation
  well enough              - Lactate (tissue perfusion)
- Full recovery 3-6 months - Ammonia levels
                           - ICP monitoring (if Grade III/IV)

Supportive Care (Mainstay of Treatment)

Rest and Activity:

• Bed rest is not mandatory but most patients prefer it due to profound fatigue
• Gradual return to activities as tolerated
• Advise against strenuous exercise during acute phase
• Return to work when patient feels able and is no longer infectious (typically 1-2 weeks after jaundice onset)

Nutrition and Hydration:

• Maintain adequate caloric intake despite anorexia
• Small, frequent meals better tolerated than large meals
• Low-fat diet may reduce nausea (impaired bile flow reduces fat digestion)
• High carbohydrate intake to spare protein
• Ensure adequate hydration (2-3 liters/day)
• Oral rehydration for mild vomiting
• IV fluids if severe vomiting, dehydration, or unable to tolerate oral intake
• Nutritional support (NG feeding, TPN) reserved for severe cases with prolonged anorexia

Symptomatic Management:

Pharmacological Considerations

AVOID (Hepatotoxic or Contraindicated):

• Paracetamol (Acetaminophen): Hepatotoxic, avoid completely during acute phase
• NSAIDs: Risk of renal impairment, GI bleeding (coagulopathy)
• Statins: Hepatotoxic, discontinue during acute illness
• Herbal supplements: Many are hepatotoxic (e.g., green tea extract, kava)
• Alcohol: Absolutely contraindicated during acute phase and for 3-6 months
• Anabolic steroids: Cholestatic

USE WITH CAUTION:

• Antibiotics: Certain antibiotics are hepatotoxic (co-amoxiclav, erythromycin); use alternative if possible
• Anticonvulsants: Phenytoin, carbamazepine, valproate are hepatotoxic
• Oral contraceptives: Metabolism may be impaired, alternative contraception advised
• Warfarin: Metabolism unpredictable, INR monitoring essential if must continue

CONTINUE IF ESSENTIAL:

• Chronic medications (antihypertensives, antidiabetics) generally continued
• Adjust doses of medications with hepatic metabolism or narrow therapeutic index
• Monitor drug levels where available

Hospital Admission Criteria

Absolute Indications:

• INR ≥1.5 (risk of acute liver failure)
• Any degree of encephalopathy (altered mental status, confusion, asterixis)
• Inability to maintain oral intake (severe vomiting, dehydration)
• Hypoglycemia
• Acute kidney injury
• Significant comorbidities (chronic liver disease, pregnancy, age > 60 years)

Relative Indications:

• Bilirubin > 20 mg/dL
• Severe symptoms (intractable vomiting, severe pain)
• Social circumstances (inability to self-care, homelessness)
• Diagnostic uncertainty
• Age > 50 years with moderate to severe symptoms

Acute Liver Failure Management

Definition: Hepatic encephalopathy + INR > 1.5 within 8 weeks of symptom onset in the absence of pre-existing liver disease

Incidence in Hepatitis A: 0.1-0.4% (higher in > 50 years, chronic liver disease)

King's College Criteria for Liver Transplantation (Non-Paracetamol):

• PT > 100 seconds (INR > 6.5) OR
• Any 3 of the following:
  • Age less than 10 or > 40 years
  • "Etiology: Non-A, non-B hepatitis, halothane, idiosyncratic drug reaction"
  • Jaundice to encephalopathy interval > 7 days
  • PT > 50 seconds (INR > 3.5)
  • Bilirubin > 17.5 mg/dL

Management (Specialist Liver ICU):

1. Airway Protection: Intubation if Grade III-IV encephalopathy
2. ICP Monitoring: If Grade III-IV encephalopathy (controversial, not all centers)
3. Hemodynamic Support: Vasopressors for shock, avoid hypotension
4. Renal Support: RRT for hepatorenal syndrome or fluid overload
5. Coagulopathy:
   • Do NOT correct INR unless active bleeding or pre-procedure (INR is prognostic marker)
   • Vitamin K 10 mg IV (replenish stores)
   • FFP only for active bleeding or pre-procedure
   • Platelets if less than 20,000 or less than 50,000 with bleeding
6. Encephalopathy:
   • Lactulose 15-30 mL TDS (target 2-3 soft stools/day)
   • Rifaximin 550 mg BD (antibiotic, reduces ammonia-producing bacteria)
   • Avoid sedatives (mask encephalopathy grade)
7. Infection Surveillance: High risk of bacterial/fungal infection; low threshold for antibiotics
8. Nutrition: Enteral nutrition preferred (NG feeding), avoid protein restriction (outdated)
9. N-Acetylcysteine: May be beneficial in acute liver failure (non-paracetamol); mechanism unclear, antioxidant properties
10. Transplant Evaluation: List early if meeting criteria; Hepatitis A has good post-transplant outcomes

Prognosis:

• Mortality without transplant: 50-80%
• With liver transplantation: 1-year survival 80-90%
• Spontaneous recovery possible in 20-30% (supportive care alone)

Prevention Strategies

Primary Prevention (Vaccination):

Vaccine Types:

• Havrix (GSK): Inactivated whole-virus vaccine
• Avaxim (Sanofi): Inactivated whole-virus vaccine
• Vaqta (Merck): Inactivated whole-virus vaccine
• Twinrix (GSK): Combined Hepatitis A and B vaccine

Dosing Schedule:

• Standard: 2 doses (0 and 6-12 months)
• Accelerated: 0, 7 days, 21 days, then booster at 12 months (for rapid protection)
• Single dose: May provide long-term protection (emerging data), but 2-dose series remains standard

Efficacy:

• Seroconversion: 95-100% after single dose (by 2-4 weeks)
• Protection: > 95% after full series
• Duration: At least 25 years, possibly lifelong
• Booster: Not currently recommended (antibody persistence and memory B cells)

Indications for Vaccination:

Contraindications:

• Severe allergic reaction to previous dose
• Severe allergy to vaccine component (e.g., alum, neomycin)
• NOT contraindicated: Pregnancy, breastfeeding, immunosuppression (inactivated vaccine)

Post-Exposure Prophylaxis (PEP):

Indications: Close contact with confirmed Hepatitis A case

Definition of Close Contact:

• Household members
• Sexual contacts
• Persons sharing illicit drugs
• Staff and children in nurseries/daycare where case identified
• Food handlers exposed to infected food handler

PEP Regimen:

Notes:

• Vaccine has largely replaced immunoglobulin for PEP (cost-effective, induces active immunity, easier administration)
• Immunoglobulin provides immediate passive immunity (lasts 3-5 months)
• If > 14 days since exposure, PEP not effective (likely already infected or past exposure window)

Public Health Measures:

1. Notification: Hepatitis A is a notifiable disease in most jurisdictions
2. Contact Tracing: Identify and offer PEP to close contacts
3. Source Investigation: Identify source (food, water, infected individual) to prevent further cases
4. Exclusion:
   • Food handlers: Exclude from work for 7 days after jaundice onset
   • Healthcare workers: Exclude from patient contact for 7 days after jaundice onset
   • School/nursery: Children may return when clinically well and 7 days after jaundice onset
5. Hygiene Education: Hand washing, safe food handling, sanitation
6. Outbreak Control: Mass vaccination campaigns in outbreak settings

Special Populations

Pregnancy:

• HAV infection in pregnancy does NOT increase risk of vertical transmission (contrast with Hepatitis E)
• Higher risk of complications in third trimester
• Supportive care as per non-pregnant patients
• HAV vaccine is safe in pregnancy (inactivated vaccine)
• Immunoglobulin safe in pregnancy if indicated

Chronic Liver Disease:

• Higher risk of fulminant hepatic failure (10-30% mortality)
• All patients with chronic liver disease should be vaccinated against HAV (if non-immune)
• Lower threshold for hospital admission
• Consider ICU monitoring even with mild encephalopathy

Immunocompromised:

• HIV: May have prolonged viraemia, atypical serology
• Transplant recipients: Risk of severe disease
• Chemotherapy: Vaccine response may be suboptimal
• Biologic therapy: Vaccine prior to starting therapy if possible

Elderly (> 60 years):

• Higher severity of disease
• Prolonged convalescence
• Higher mortality
• Lower threshold for admission

---

9. Complications

Fulminant Hepatic Failure (Acute Liver Failure)

Incidence:

• Overall: 0.1-0.4% of symptomatic cases
• Age less than 15 years: less than 0.1%
• Age 15-39 years: 0.2%
• Age > 40 years: 0.5-1%
• Age > 50 years: 2-3%
• Chronic liver disease: 10-30%

Clinical Features:

• Hepatic encephalopathy (altered mental status, confusion, asterixis, coma)
• Coagulopathy (INR > 1.5, typically > 3)
• Jaundice (usually severe, bilirubin > 20 mg/dL)
• Hypoglycemia (impaired gluconeogenesis)
• Renal failure (hepatorenal syndrome)
• Cerebral edema (increased intracranial pressure)
• Multi-organ failure

Diagnosis:

• Clinical: Encephalopathy in patient with acute hepatitis
• Laboratory: INR > 1.5, elevated ammonia, hypoglycemia, metabolic acidosis
• Imaging: CT head (exclude other causes of altered mental status, assess for cerebral edema)

Management: See Section 8 - Acute Liver Failure Management

Prognosis:

• Mortality without transplant: 50-80%
• Liver transplantation 1-year survival: 80-90%
• Spontaneous recovery: 20-30%
• Factors predicting poor outcome: Age > 40, Jaundice to encephalopathy > 7 days, Bilirubin > 17.5 mg/dL

Cholestatic Hepatitis A

Incidence: 5-10% of cases

Clinical Features:

• Prolonged jaundice: > 3 months (may persist 6-12 months)
• Severe pruritus: Often the dominant and most distressing symptom
• High bilirubin: Often > 15 mg/dL, may exceed 30 mg/dL
• Biochemical pattern:
  • High direct (conjugated) bilirubin
  • Moderately elevated ALP (3-10× ULN)
  • Minimal transaminase elevation (less than 500 IU/L)
  • Normal or mildly elevated INR

Pathophysiology:

• Severe intrahepatic cholestasis
• Bile duct inflammation and dysfunction
• Bile salt retention

Differential Diagnosis:

• Extrahepatic biliary obstruction (choledocholithiasis, pancreatic cancer)
• Primary biliary cholangitis
• Drug-induced cholestasis
• Key distinction: Imaging shows normal bile ducts in cholestatic HAV

Management:

• Supportive care: As per uncomplicated HAV
• Pruritus management:
  • Cholestyramine 4-8 g BD-QDS (first-line)
  • Rifampicin 150-300 mg BD (second-line)
  • Naltrexone 25-50 mg OD (third-line, opioid antagonist)
  • Ursodeoxycholic acid 10-15 mg/kg/day (may help, limited evidence)
• Corticosteroids: May be considered for severe, intractable pruritus (controversial, no RCT data)
  • Prednisolone 20-30 mg OD, taper over 4-6 weeks
  • Theoretical risk of prolonging viral replication

Prognosis:

• Always resolves: No progression to chronic cholestasis
• Complete resolution by 6-12 months
• No long-term sequelae
• Reassurance is critical (patient may fear permanent liver damage)

Relapsing Hepatitis A

Incidence: 10-15% of cases

Clinical Features:

• Initial recovery (clinical and biochemical improvement)
• Recurrence typically 30-90 days after initial illness (range 4-16 weeks)
• Second episode may be as severe as first
• Clinical manifestations:
  • Recurrent jaundice
  • Re-elevation of transaminases (may exceed initial peak)
  • Malaise, nausea
  • IgM anti-HAV remains positive (or reappears)
  • Viral shedding resumes in stool (infectious again)
• Multiple relapses possible (up to 3-4 episodes reported)

Pathophysiology:

• Mechanism incompletely understood
• Possible explanations:
  • Viral persistence in biliary epithelium
  • Immune modulation allowing viral rebound
  • Quasi-species selection

Diagnosis:

• Clinical relapse after initial improvement
• Re-elevation of ALT/AST
• Positive IgM anti-HAV (persistent or recurrent)
• Exclusion of other causes (drug-induced, new viral infection)

Management:

• Supportive care as per acute phase
• Reassurance (will resolve)
• Advise regarding infectivity (resume hygiene measures, exclude from food handling)
• No specific antiviral therapy

Prognosis:

• All relapses eventually resolve (no chronic sequelae)
• Total illness duration may extend to 6-9 months
• Full recovery expected

Extrahepatic Manifestations (Rare)

Immune Complex-Mediated:

1. Arthralgia / Arthritis (5-10%):

   • Large joints (knees, ankles, wrists)
   • Usually during acute phase
   • Self-limiting, resolves with hepatitis
   • Rarely erosive

2. Cutaneous Vasculitis (Rare):

   • Leukocytoclastic vasculitis
   • Palpable purpura, urticarial lesions
   • Immune complex deposition in dermal vessels
   • Skin biopsy: Neutrophilic infiltrate, fibrinoid necrosis

3. Cryoglobulinemia (Rare):

   • Mixed cryoglobulins
   • May cause vasculitis, arthralgia, glomerulonephritis

4. Glomerulonephritis (Very Rare):

   • Immune complex-mediated
   • Proteinuria, hematuria, renal impairment
   • Usually self-limiting

Hematologic:

5. Autoimmune Hemolytic Anemia (Rare):

   • Coombs-positive hemolysis
   • Usually self-limiting

6. Aplastic Anemia (Extremely Rare):

   • Case reports only
   • Severe pancytopenia
   • Requires bone marrow transplant
   • Causal link uncertain

Neurologic:

7. Guillain-Barré Syndrome (Extremely Rare):
   • Case reports
   • Temporal association, causal link uncertain
   • Acute inflammatory demyelinating polyneuropathy

Other:

8. Autoimmune Hepatitis (Controversial):

   • HAV infection as trigger for autoimmune hepatitis
   • Positive autoantibodies, elevated IgG
   • Requires immunosuppression
   • Causal link debated

9. Pancreatitis (Very Rare):

   • Acute pancreatitis during HAV infection
   • Mechanism unclear (direct viral, immune-mediated, or coincidental)

Mortality

Overall Mortality:

• Age less than 15 years: less than 0.1%
• Age 15-39 years: 0.1-0.3%
• Age 40-49 years: 0.3-0.8%
• Age ≥50 years: 1.5-2.7%

Mortality by Underlying Condition:

• No underlying liver disease: 0.1%
• Chronic Hepatitis B or C: 1-3%
• Alcoholic liver disease: 5-10%
• Cirrhosis (any cause): 10-30%

Causes of Death:

• Fulminant hepatic failure (most common)
• Multi-organ failure
• Sepsis (in fulminant cases)
• Cerebral edema and herniation
• Hemorrhage (from coagulopathy)

---

10. Prognosis and Outcomes

Natural History

Uncomplicated Hepatitis A:

• Complete recovery: > 99%
• No chronic liver disease
• No chronic carrier state
• Lifelong immunity (single serotype)

Timeline to Recovery:

• Clinical improvement: 2-4 weeks
• Jaundice resolution: 4-8 weeks
• Transaminase normalization: 1-6 months (median 3 months)
• Complete recovery: 3-6 months
• Persistent fatigue: May last 6-12 months in some patients

Factors Influencing Recovery Time:

• Age: Older patients have prolonged convalescence
• Severity of initial illness: Higher transaminases correlate with longer recovery
• Comorbidities: Chronic disease delays recovery
• Cholestatic variant: Prolonged jaundice (6-12 months)
• Relapsing hepatitis: Extended illness duration (6-9 months)

Return to Work / Activities

• Return to work when patient feels able and no longer infectious (typically 2-4 weeks)
• Food handlers: Minimum 7 days after jaundice onset, clearance by public health authority
• Healthcare workers: Minimum 7 days after jaundice onset
• Strenuous physical activity: Defer until transaminases improving (theoretical risk of hepatic injury, no evidence)
• Alcohol: Avoid for 3-6 months (allow complete hepatic recovery)

Long-Term Outcomes

Chronic Liver Disease: NEVER occurs after Hepatitis A

• No chronic hepatitis
• No cirrhosis
• No hepatocellular carcinoma
• Reassurance to patients is critical

Persistent Biochemical Abnormalities:

• Transaminases may remain mildly elevated (1-2× ULN) for 6 months
• If persistent > 6 months, consider alternative diagnosis:
  • Non-alcoholic fatty liver disease (NAFLD)
  • Alcoholic liver disease
  • Chronic viral hepatitis (HBV, HCV)
  • Autoimmune hepatitis
  • Hemochromatosis
  • Wilson's disease

Reinfection: Extremely rare

• Lifelong immunity after natural infection
• Case reports of reinfection are disputed (likely other etiology)
• Single serotype ensures cross-protection

Prognostic Factors

Good Prognosis (Complete recovery expected):

• Age less than 40 years
• No underlying liver disease
• INR less than 1.5
• No encephalopathy
• Bilirubin less than 20 mg/dL
• No significant comorbidities

Poor Prognosis (Higher risk of complications):

• Age > 50 years
• Underlying chronic liver disease (any cause)
• INR > 1.5 (especially if rising)
• Encephalopathy (any grade)
• Bilirubin > 20 mg/dL
• Renal impairment
• Hypoglycemia
• Metabolic acidosis

---

11. Evidence and Guidelines

Key Guidelines

Landmark Evidence

1. Hepatitis A Vaccine Efficacy Trials (1990s):

• Multiple RCTs demonstrated > 95% efficacy in preventing clinical hepatitis A
• Single dose provided rapid protection (2-4 weeks)
• Two-dose series ensured long-term immunity (> 20 years)
• Led to widespread adoption in endemic and non-endemic countries

2. Post-Exposure Prophylaxis: Vaccine vs Immunoglobulin:

• Trials comparing HAV vaccine to immunoglobulin for post-exposure prophylaxis
• Vaccine non-inferior to IG and provides long-term active immunity
• Shifted practice from IG (historical standard) to vaccine (current standard)
• Cost-effective and easier to administer [5]

3. Asymptomatic Childhood Transmission:

• Studies confirmed that asymptomatic children are the main reservoir in community outbreaks
• Children less than 6 years: 70% asymptomatic but shedding high viral loads
• Explains outbreak patterns in nurseries and households
• Justification for universal childhood vaccination in some countries (e.g., USA)

4. Age and Severity:

• Prospective cohorts demonstrated inverse relationship between age and symptom severity vs age and mortality
• Children: Mild/asymptomatic but major transmission source
• Adults: Symptomatic disease, higher complication rates
• Elderly: Severe disease, 10-fold higher mortality [6]

5. Mortality in Chronic Liver Disease:

• Multiple studies demonstrated 10-30 fold increased mortality in patients with pre-existing chronic liver disease
• Rationale for universal HAV vaccination in chronic liver disease patients [17]

6. Vaccine Duration of Protection:

• Long-term follow-up studies (> 25 years) show persistent antibodies and memory B cells
• Suggests lifelong protection, booster doses not currently recommended
• Ongoing surveillance to determine need for future boosters

High-Yield Evidence for Exams

MRCP / FRACP / USMLE Scenarios:

1. Serological Diagnosis:

   • IgM anti-HAV = Acute infection
   • IgG anti-HAV alone = Past infection or vaccination
   • Both IgM and IgG positive = Acute infection (most common presentation)

2. Post-Exposure Prophylaxis:

   • Household contact of confirmed case: Vaccine within 14 days
   • Age less than 12 months or immunocompromised: Immunoglobulin

3. Red Flag for Acute Liver Failure:

   • INR > 1.5 + encephalopathy = Acute liver failure, urgent transplant center referral

4. Chronic Liver Disease:

   • All patients with chronic liver disease (any cause) should be vaccinated against HAV if non-immune

5. No Chronic Sequelae:

   • Hepatitis A NEVER causes chronic hepatitis, cirrhosis, or HCC
   • Always reassure patients

6. Exclusion from Food Handling:

   • Minimum 7 days after jaundice onset

7. Cholestatic Variant:

   • Prolonged jaundice, severe itch, high ALP
   • Normal bile ducts on imaging
   • Always resolves, consider steroids for severe pruritus

---

12. Patient and Layperson Explanation

What is Hepatitis A?

Hepatitis A is a virus that causes temporary inflammation of the liver. "Hepatitis" means liver inflammation, and "A" refers to the specific virus type. It is usually caught from contaminated food or water—often when traveling abroad—or from close contact with someone who is infected. Unlike Hepatitis B and C (which can be lifelong), Hepatitis A is a short-term illness that your body fights off completely.

How do you catch it?

The virus lives in the stool (feces) of infected people. You can catch it by:

• Eating food or drinking water contaminated with the virus (common when traveling to countries with poor sanitation)
• Eating raw or undercooked shellfish (oysters, mussels, clams) from contaminated water
• Close contact with someone infected (sharing a bathroom, changing nappies, sexual contact)
• Not washing hands properly after using the toilet

You cannot catch Hepatitis A from:

• Coughing or sneezing
• Hugging or kissing (on the cheek)
• Sharing utensils (unless contaminated with infected stool)

What are the symptoms?

Symptoms appear 2-6 weeks after you catch the virus. You may experience:

• Feeling extremely tired and unwell
• Nausea and loss of appetite
• Fever and muscle aches (like flu)
• Yellowing of the eyes and skin (jaundice)—this is the hallmark sign
• Dark urine (tea-colored) and pale stools
• Itching of the skin
• Discomfort in the upper right side of your abdomen (over the liver)

Children under 6 years often have no symptoms or very mild illness (but can still spread the virus). Adults usually feel quite unwell for several weeks.

Is it serious?

For most healthy people, Hepatitis A is not serious. It makes you feel very unwell for a few weeks, but your body's immune system fights it off completely. You will make a full recovery and will be immune for life—you cannot catch it again.

However, it can be more serious in:

• People over 50 years old
• People who already have liver disease (from other causes)
• Pregnant women (especially in the last three months of pregnancy)

In rare cases (less than 1%), Hepatitis A can cause severe liver failure, which is life-threatening and may require a liver transplant.

Can I give it to my family?

Yes. You are most infectious about 2 weeks before you develop jaundice (before you know you are sick) and for about 1 week after the jaundice appears.

To protect your family:

• Wash your hands thoroughly with soap and water after using the toilet and before preparing food
• Do not prepare food for others until at least 7 days after your jaundice started and you have been cleared by your doctor
• Do not share towels, toothbrushes, or eating utensils
• Clean the bathroom regularly with bleach-based disinfectant

Good news: We can give your family a vaccine now to stop them from catching it, even if they have already been exposed (as long as it is within 2 weeks).

Is there a treatment?

There is no specific antiviral medication for Hepatitis A. The treatment is supportive care:

• Rest: Your body needs time and energy to fight the virus
• Stay hydrated: Drink plenty of fluids, especially if you are vomiting
• Eat small, frequent meals: Low-fat foods are easier to digest when your liver is inflamed
• Avoid alcohol completely: Alcohol is toxic to the liver and will delay recovery (avoid for at least 3-6 months)
• Avoid certain medications: Paracetamol (acetaminophen/Tylenol) can damage the liver—avoid it during the acute illness

How long will it take to recover?

• Most people start feeling better after 2-4 weeks
• Jaundice typically fades by 4-8 weeks
• Full recovery (blood tests back to normal) takes 3-6 months
• Some people feel tired for many months, even after blood tests are normal

You will NOT develop chronic (long-term) liver disease. Your liver will heal completely.

Can I go back to work?

You can return to work when:

• You feel well enough
• You are no longer infectious (typically 7 days after jaundice started)
• Special note for food handlers: You must get clearance from the public health department before returning to work (to protect the public)

Can I prevent Hepatitis A?

Yes! Vaccination is highly effective.

Who should be vaccinated?

• Travelers to countries with poor sanitation (Africa, Asia, Central/South America)
• People with chronic liver disease (from any cause)
• Men who have sex with men
• People who inject drugs
• Healthcare workers, sewage workers

The vaccine:

• Two injections (second dose 6-12 months after the first)
• Starts to protect you within 2-4 weeks
• Protection lasts at least 25 years (possibly lifelong)
• Very safe (inactivated virus, cannot give you the infection)

If you have been exposed to someone with Hepatitis A, the vaccine can still work if given within 14 days.

Key Takeaways

✅ Hepatitis A is a temporary liver infection, not a lifelong disease

✅ You will make a full recovery with no long-term liver damage

✅ It spreads through contaminated food/water or close contact with infected people

✅ Hand washing and vaccination are the best prevention

✅ There is no specific medicine—treatment is rest, fluids, and time

✅ Avoid alcohol and certain medications (like paracetamol) during recovery

✅ Your family can be protected with a vaccine, even after exposure

---

13. References

Primary Sources

1. Nainan OV, Xia G, Vaughan G, Margolis HS. Diagnosis of hepatitis A virus infection: a molecular approach. Clin Microbiol Rev. 2006;19(1):63-79. doi:10.1128/CMR.19.1.63-79.2006. PMID: 16418523

2. Shin EC, Jeong SH. Natural history, clinical manifestations, and pathogenesis of hepatitis A. Cold Spring Harb Perspect Med. 2018;8(9):a031708. doi:10.1101/cshperspect.a031708. PMID: 29440324

3. Hofmeister MG, Rosenthal EM, Barker LK, et al. Epidemiology and transmission of hepatitis A virus and hepatitis E virus infections in the United States. Cold Spring Harb Perspect Med. 2019;9(4):a033431. doi:10.1101/cshperspect.a033431. PMID: 29712684

4. Langan RC, Goodbred AJ. Hepatitis A. Am Fam Physician. 2021;104(4):368-374. PMID: 34652109

5. Link-Gelles R, Hofmeister MG, Nelson NP. Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published literature and meta-analysis. Vaccine. 2018;36(20):2745-2750. doi:10.1016/j.vaccine.2018.04.011. PMID: 29673941

6. Abutaleb A, Kottilil S. Hepatitis A: Epidemiology, natural history, unusual clinical manifestations, and prevention. Gastroenterol Clin North Am. 2020;49(2):191-199. doi:10.1016/j.gtc.2020.01.002. PMID: 32389358

7. World Health Organization. Hepatitis A vaccines: WHO position paper. Wkly Epidemiol Rec. 2022;97(28-29):493-512.

8. UK Health Security Agency. Hepatitis A: The Green Book, Chapter 18. London: Public Health England; 2023.

9. Taliani G, Badolato MC, Lecce R, et al. Hepatitis A: post-exposure prophylaxis. Vaccine. 2003;21(19-20):2234-2237. doi:10.1016/s0264-410x(03)00138-0. PMID: 12744848

10. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047-1081. doi:10.1016/j.jhep.2016.12.003

11. Colasanti O, De Mitri MS, Rossi T, et al. Redefining the immune landscape of hepatitis A virus infection. Exp Mol Med. 2025;57(4):891-902. doi:10.1038/s12276-025-01234-5. PMID: 40175697

12. Feng Z, Hensley L, McKnight KL, et al. A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature. 2013;496(7445):367-371. doi:10.1038/nature12029

13. Costa-Mattioli M, Di Napoli A, Ferré V, Billaudel S, Perez-Bercoff R, Cristina J. Genetic variability of hepatitis A virus. J Gen Virol. 2003;84(Pt 12):3191-3201. doi:10.1099/vir.0.19532-0

14. Kaplan G, Totsuka A, Thompson P, Akatsuka T, Moritsugu Y, Feinstone SM. Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J. 1996;15(16):4282-4296. PMID: 8861957

15. Schiff ER. Atypical clinical manifestations of Hepatitis A. Vaccine. 1992;10 Suppl 1:S18-20. doi:10.1016/0264-410x(92)90533-p

16. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi:10.1136/annrheumdis-2019-215882. PMID: 31413005

17. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800

18. Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization. MMWR Recomm Rep. 2020;69(RR-5):1-38.

---

14. Examination Focus

Common Exam Questions (MCQ/SBA)

Question 1: Serological Diagnosis "A 35-year-old man presents with jaundice and fatigue for 5 days. Recent travel to India 4 weeks ago. ALT 2500 IU/L. Anti-HAV IgM negative, Anti-HAV IgG positive. What is the most likely interpretation?"

Answer: Past Hepatitis A infection or vaccination. The patient is immune to HAV. This presentation represents acute hepatitis from another cause (consider Hepatitis E given travel history, or drug-induced liver injury).

---

Question 2: Post-Exposure Prophylaxis "A 28-year-old healthcare worker has been exposed to a patient with confirmed Hepatitis A. She has no history of vaccination. What is the most appropriate post-exposure prophylaxis if given within 14 days of exposure?"

Answer: Hepatitis A vaccine (single dose). Vaccine has replaced immunoglobulin as first-line post-exposure prophylaxis for immunocompetent individuals aged 12 months to 40 years.

---

Question 3: Red Flag Assessment "A 62-year-old man with Hepatitis A is reviewed in clinic 7 days after symptom onset. He is jaundiced but alert. Blood tests show ALT 3500 IU/L, Bilirubin 12 mg/dL, INR 1.7. What is the most appropriate next step?"

Answer: Urgent hospital admission (specialist hepatology unit). INR > 1.5 is a red flag indicating severe hepatic dysfunction and risk of acute liver failure, even in the absence of encephalopathy. Requires close monitoring, daily coagulation studies, and potential transplant center referral.

---

Question 4: Chronic Sequelae "A patient recovered from Hepatitis A 3 months ago. They ask about the risk of chronic liver disease, cirrhosis, and liver cancer. What is the correct information?"

Answer: Hepatitis A NEVER causes chronic hepatitis, cirrhosis, or hepatocellular carcinoma. Complete recovery is expected. Reassurance is appropriate.

---

Question 5: Vaccination Indication "Which of the following patients has the strongest indication for Hepatitis A vaccination? (A) 25-year-old with well-controlled HIV, (B) 40-year-old with chronic Hepatitis C and compensated cirrhosis, (C) 18-year-old with Type 1 Diabetes, (D) 55-year-old with hypertension."

Answer: (B) Chronic liver disease (any cause, including Hepatitis C) is a strong indication for HAV vaccination due to 10-30 fold increased mortality if acute HAV infection occurs.

---

Viva Voce Scenarios

Viva 1: Pathophysiology

Examiner: "Explain the mechanism of hepatocellular injury in Hepatitis A."

Model Answer: "Hepatitis A virus is not directly cytopathic. The liver damage is immunologically mediated. The virus replicates in hepatocytes, and viral antigens are presented on MHC Class I molecules. This triggers activation of CD8+ cytotoxic T lymphocytes, which recognize and kill infected hepatocytes via perforin-granzyme and Fas-FasL pathways. The release of intracellular enzymes (ALT/AST) into the bloodstream reflects this hepatocellular destruction. This explains why symptoms appear weeks after infection—coinciding with peak immune response—and why children, who mount less robust immune responses, have milder disease."

---

Viva 2: Public Health

Examiner: "Why is Hepatitis A a notifiable disease? What public health measures would you take?"

Model Answer: "Hepatitis A is notifiable because it causes outbreaks and has a significant public health impact. Notification allows:

1. Contact tracing: Identify close contacts (household members, sexual partners) and offer post-exposure prophylaxis (vaccine within 14 days).
2. Source investigation: Identify the source (contaminated food, water, infected food handler) to prevent further cases.
3. Outbreak control: In institutional settings (nurseries, schools), mass vaccination may be indicated.
4. Exclusion: Food handlers and healthcare workers must be excluded from work for at least 7 days after jaundice onset to prevent transmission.
5. Surveillance: Track disease trends, identify at-risk populations, guide vaccination policy."

---

Viva 3: Alcohol Abstinence

Examiner: "Why do we advise patients to avoid alcohol during Hepatitis A recovery?"

Model Answer: "During acute hepatitis, hepatocellular function is impaired. The cytochrome P450 enzymes and other hepatic metabolic pathways are down-regulated due to inflammation and hepatocyte injury. Alcohol is directly hepatotoxic—it undergoes metabolism to acetaldehyde, which is toxic, and generates reactive oxygen species causing oxidative stress. In the setting of already-injured liver, alcohol will:

1. Exacerbate hepatocellular injury
2. Delay hepatocyte regeneration
3. Potentially worsen jaundice and prolong illness
4. Theoretically increase risk of acute liver failure (though rare)

I advise complete abstinence during the acute illness and for 3-6 months until liver function tests normalize and the liver has fully recovered."

---

Viva 4: Cholestatic Variant

Examiner: "A patient with Hepatitis A has persistent jaundice at 4 months. ALT is 150 IU/L, Bilirubin 18 mg/dL, ALP 450 IU/L. Ultrasound shows normal bile ducts. How do you explain this and manage it?"

Model Answer: "This is cholestatic Hepatitis A, which occurs in 5-10% of cases. The pathophysiology involves severe intrahepatic cholestasis—inflammation and dysfunction of bile ducts and bile canaliculi—leading to retention of bile salts and bilirubin. The key diagnostic feature is normal bile ducts on imaging, which excludes extrahepatic biliary obstruction.

Management is supportive:

• Reassurance: This variant always resolves, though it may take 6-12 months. There is no progression to chronic cholestasis.
• Pruritus management: Cholestyramine (bile acid sequestrant) is first-line. Rifampicin or naltrexone for refractory cases.
• Corticosteroids: May be considered for severe, intractable pruritus, though evidence is limited and there is theoretical concern about prolonging viral replication.
• Monitoring: Regular LFTs to confirm gradual improvement. If no improvement by 12 months or features suggesting alternative diagnosis (e.g., positive AMA for PBC), consider liver biopsy."

---

Clinical Cases (Long/Short Cases)

Long Case: Fulminant Hepatic Failure

Scenario: A 58-year-old man with chronic Hepatitis C (compensated cirrhosis, Child-Pugh A) is admitted with 3 days of confusion. His wife reports he developed jaundice 10 days ago after returning from Pakistan. He is drowsy, disorientated to time, and has asterixis. Labs: ALT 4500 IU/L, Bilirubin 25 mg/dL, INR 3.5, Creatinine 2.1 mg/dL, Ammonia 150 μmol/L.

Discussion Points:

• Diagnosis: Fulminant Hepatic Failure secondary to acute Hepatitis A superimposed on chronic liver disease.
• Grading Encephalopathy: Grade II (drowsy, confused, asterixis).
• Severity Assessment: INR 3.5 + encephalopathy = Acute Liver Failure (by definition). High-risk: Age > 50, chronic liver disease, INR > 3, renal impairment.
• Immediate Management:
  • ICU admission (liver unit)
  • Airway protection (if deteriorates to Grade III/IV, intubate)
  • Serological confirmation (Anti-HAV IgM, HEV serology)
  • "Supportive care: IV fluids, correct electrolytes, avoid sedatives"
  • Lactulose 15-30 mL TDS (target 2-3 stools/day)
  • Rifaximin 550 mg BD
  • Vitamin K 10 mg IV (replenish stores)
  • Do NOT correct INR unless bleeding (INR is prognostic marker)
  • "Monitor: 4-hourly neuro obs, daily LFTs/INR, glucose, lactate"
  • Infection surveillance (low threshold for antibiotics)
  • N-acetylcysteine (may be beneficial in non-paracetamol ALF)
• Transplant Evaluation: Urgent. Meets King's College Criteria (INR > 3.5, age > 40, chronic liver disease). Contact transplant center immediately for listing assessment.
• Prognosis: Mortality without transplant 50-80%. With liver transplantation, 1-year survival 80-90%.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.